OpenBench, Inc., an emerging leader in AI-enabled small molecule discovery, entered into an agreement with HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, to use the OpenBench virtual screening platform to identify novel, potent inhibitors of an undisclosed rare disease target. Under the terms of the agreement, OpenBench will receive payment for successful identification and experimental confirmation of novel chemotypes that meet HemoShear's potency and developability criteria. Financial terms were not disclosed. "We are excited to support HemoShear's efforts to identify clinically relevant therapeutic candidates for a rare disease with significant unmet patient need," said OpenBench CTO James Yoder. "We feel confident that the OpenBench technology will pair nicely with the HemoShear REVEAL-Tx platform to help identify potent, developable hits and optimize the likelihood of success for this HemoShear discovery program."